MedTrace Logo

Cytokeratin 8 Level in Age-related Macular Degeneration

NCT02707575 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2020-12-09

No results posted yet for this study

Summary

The investigators will evaluate the concentrations of cytokeratin 8 in aqueous humor in eyes with exudative age-related macular degeneration (AMD) before therapy with intravitreal Ranibizumab, and identify associations with visual and anatomical outcome after treatment.

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab

Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.

Sponsors & Collaborators

  • Konkuk University

    collaborator OTHER

  • Inje University

    collaborator OTHER

  • Novartis

    collaborator INDUSTRY

  • Severance Hospital

    collaborator OTHER

  • Gangnam Severance Hospital

    lead OTHER

Principal Investigators

  • Suk Ho Byeon, MD. Ph.D. · Professor. Yonsei University

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-26
Primary Completion
2018-03-12
Completion
2018-04-23

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02707575 on ClinicalTrials.gov